Assembly Biosciences, Inc.
ASMB
Rank in Stocks
#12733
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development... Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Share Price
$21.79
Last synced: 2026-11-09
Market Cap
$443.66M
Change (1 day)
6.71%
Change (1 year)
-34.23%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Assembly Biosciences, Inc. (ASMB)
Category
Healthcare
Operating Margin for Assembly Biosciences, Inc. (ASMB)
Operating Margin as of November 2026 TTM: -11.75%
According to Assembly Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is -11.75%. At the end of 2025 the company had an operating margin of -16.76%.
Operating Margin history for Assembly Biosciences, Inc. from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -11.75% | -29.89% |
| 2025 | -16.76% | -89.48% |
| 2024 | -159.26% | -82.35% |
| 2023 | -902.50% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -2,121.65% | 2,490.85% |
| 2020 | -81.89% | -87.27% |
| 2019 | -643.44% | 2.72% |
| 2018 | -626.42% | 8.17% |
| 2017 | -579.09% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -103.28% |
US
|
|
| -149.01% | -87.32% |
US
|
|
| 25.57% | -102.18% |
AU
|
|
| 31.23% | -102.66% |
BE
|
|
| 29.35% | -102.50% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Assembly Biosciences, Inc.'s operating margin
What is Assembly Biosciences, Inc.'s operating margin?
Assembly Biosciences, Inc.'s operating margin is -11.75%, as of Nov 2026.
What was Assembly Biosciences, Inc.'s operating margin in 2025?
In 2025, Assembly Biosciences, Inc.'s operating margin was -16.76%, compared with -159.26% in 2024.
How has Assembly Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Assembly Biosciences, Inc.'s operating margin was highest in 2022 (0.00%) and lowest in 2021 (-2,121.65%).
How does Assembly Biosciences, Inc.'s operating margin compare with similar companies?
Assembly Biosciences, Inc.'s operating margin (-11.75%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.